secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001193125-22-211843
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir Q2 net loss $44.6M; $126.5M July offering extends cash runway for Phase 3 trials
--------------------------------------------------------------------------------

- Net loss $44.6M ($0.69/sh) vs $37.6M ($0.60/sh) in Q2 2021; R&D expense rose to $31.4M.
- Cash $172.7M at June 30; July registered direct offering raised $126.5M to fund three Phase 3 posoleucel trials.
- Phase 2 multi-virus prevention final data expected year-end; Phase 2 BKV treatment topline in Q1 2023.
- Posoleucel granted EMA orphan designation for prevention; now holds three FDA RMAT designations.
- FY2022 operating expense guidance $130-145M, excluding stock-based compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312522211843/0001193125-22-211843-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312522211843/d308599d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-211843

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer